The Oswaldo Cruz Foundation (Fiocruz) at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine'. The initiative is one of the health research and development projects prioritized by the World Health Organization (WHO), aiming to ensure the access of populations from developing countries to public health tools based on cutting edge technologies. The phase II clinical studies will be carried out in a partnership involving Fiocruz, public foundation attached to the Brazilian Ministry of Health, and the Brazilian biotechnology company Orygen Biotecnologia S.A..
↧
